EDAP TMS S.A. Secures?36M Funding from European Investment Bank
PorAinvest
martes, 26 de agosto de 2025, 11:03 am ET1 min de lectura
EDAP--
The letter of intent was announced on August 26, 2025, by EDAP's Chief Executive Officer, Ryan Rhodes. Rhodes expressed pleasure with the agreement, highlighting that the capital will enhance the company's balance sheet and provide substantial low-interest funding accessible in tranches as needed. The EIB has been a longstanding partner in supporting innovative technologies that benefit millions of patients globally [1].
EDAP TMS S.A. develops, manufactures, promotes, and distributes minimally invasive medical devices worldwide using ultrasound technology. The company introduced the Focal One® in Europe and the U.S. as the leading prostate focal therapy controlled by urologists, with potential to expand to multiple indications beyond prostate cancer [1].
The credit facility is expected to close by the end of 2025, pending the signature of final legal documents. EDAP TMS S.A. has a history of delivering innovative technologies, and this latest funding will further bolster its position in the market [2].
References:
[1] https://finance.yahoo.com/news/edap-announces-letter-intent-36-110000348.html
[2] https://www.marketscreener.com/news/edap-tms-s-a-announced-that-it-expects-to-receive-36-million-in-funding-from-european-investment-b-ce7c50d9da81f620
EDAP TMS S.A. has entered into a letter of intent with the European Investment Bank to receive €36 million in funding. The company expects to close the deal by the end of 2025. The transaction will involve a credit facility, but further details were not disclosed.
EDAP TMS S.A., a leading provider of robotic energy-based therapies, has entered into a letter of intent with the European Investment Bank (EIB) to secure €36 million in funding. The company expects to close the deal by the end of 2025, with the transaction involving a credit facility. The funds will support the continued expansion of Focal One® Robotic HIFU in focal therapy, a rapidly growing treatment category for early-stage prostate cancer, and accelerate the development of new clinical indications [1].The letter of intent was announced on August 26, 2025, by EDAP's Chief Executive Officer, Ryan Rhodes. Rhodes expressed pleasure with the agreement, highlighting that the capital will enhance the company's balance sheet and provide substantial low-interest funding accessible in tranches as needed. The EIB has been a longstanding partner in supporting innovative technologies that benefit millions of patients globally [1].
EDAP TMS S.A. develops, manufactures, promotes, and distributes minimally invasive medical devices worldwide using ultrasound technology. The company introduced the Focal One® in Europe and the U.S. as the leading prostate focal therapy controlled by urologists, with potential to expand to multiple indications beyond prostate cancer [1].
The credit facility is expected to close by the end of 2025, pending the signature of final legal documents. EDAP TMS S.A. has a history of delivering innovative technologies, and this latest funding will further bolster its position in the market [2].
References:
[1] https://finance.yahoo.com/news/edap-announces-letter-intent-36-110000348.html
[2] https://www.marketscreener.com/news/edap-tms-s-a-announced-that-it-expects-to-receive-36-million-in-funding-from-european-investment-b-ce7c50d9da81f620

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios